Product Description
Crisaborole is used to treat eczema (atopic dermatitis; a skin condition which causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children 3 years of age and older. Crisaborole is in a class of medications called phosphodiesterase inhibitors. It works by blocking the action of certain natural substances in the body that cause inflammation. (Sourced from: https://medlineplus.gov/druginfo/meds/a617019.html)
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Canada | Croatia | Egypt | European Medicines Agency | Finland | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Latvia | Lebanon | Lithuania | Mexico | Poland | Portugal | Saudi Arabia | South Africa | Sweden | Taiwan | United Arab Emirates | United States | Uruguay
Approved Indications: Dermatitis | Dermatitis, Atopic
Known Adverse Events: Pain Unspecified
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Israel, Turkey, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Dermatitis, Atopic
Phase 2: Vitiligo
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05298033 | P2 |
Completed |
Vitiligo |
2024-04-30 |
|
| CrisADe Control | P3 |
Completed |
Dermatitis, Atopic |
2022-12-27 |
|
| NCT04800185 | P1 |
Completed |
Dermatitis, Atopic |
2022-04-30 |
|
| C3291035 | P3 |
Completed |
Dermatitis, Atopic |
2022-01-19 |